A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting beta2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (>=12 Years of Age) Patients With Asthma.
Phase of Trial: Phase III/IV
Latest Information Update: 20 Dec 2016
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 31 Aug 2016 According to an AstraZeneca media release, results from this study were published in The New England Journal of Medicine.
- 31 Aug 2016 Primary endpoint has been met. (Time to first event included in the definition of asthma exacerbation), as reported in an AstraZeneca media release.
- 31 Aug 2016 Results published in the Media Release
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History